Association of glucagon-like peptide-1 system with the prevention and treatment of nonalcoholic fatty liver disease
10.3969/j.issn.1001-5256.2022.06.039
- VernacularTitle:胰高血糖素样肽1系统与非酒精性脂肪性肝病防治的关系
- Author:
Hongliang CUI
1
;
Li XU
2
;
Tong LU
1
Author Information
1. College of Medical Technology, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China
2. Medical Experimental Research Center, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China
- Publication Type:Reviews
- Keywords:
Glucagon-Like Peptide 1;
Non-alcoholic Fatty Liver Disease;
Lipid Metabolism
- From:
Journal of Clinical Hepatology
2022;38(6):1406-1410
- CountryChina
- Language:Chinese
-
Abstract:
With a large number of patients, nonalcoholic fatty liver disease (NAFLD) has become one of the major chronic liver diseases that jeopardize the health of people worldwide. This article introduces the major factors in glucagon-like peptide-1 (GLP-1) system that are associated with the production, decomposition, and receptor effect of GLP-1, summarizes the regulatory mechanism of GLP-1 system on NAFLD, and proposes the main problems of GLP-1 system in the treatment of NAFLD, so as to provide a reference for the research and clinical treatment of NAFLD.
